Latest & greatest articles for obesity

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on obesity or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on obesity and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for obesity

1. Adult obesity: applying All Our Health

Adult obesity: applying All Our Health Adult obesity: applying All Our Health - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Adult obesity: applying All Our Health Updated 17 June 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team (...) , The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/adult-obesity-applying-all-our-health/adult-obesity-applying-all-our-health Introduction This guide is part of , a resource which helps health professionals prevent ill health and promote health and wellbeing as part of their everyday practice

2019 Public Health England

2. Overweight, Obesity and Contraception

Overweight, Obesity and Contraception FSRH Guideline Overweight, Obesity & Contraception April 2019 | FSRH Faculty of Sexual & Reproductive Healthcare (FSRH) provided funding to the Clinical Effectiveness Unit (of the FSRH) to assist them in the production of this guideline, Overweight, Obesity and Contraception (April 2019). Published by the Faculty of Sexual & Reproductive Healthcare. Registered in England No. 2804213 and Registered Charity No. 1019969. Copyright © Faculty of Sexual (...) . If a guideline is updated, the FSRH replace the version on its website and the BMJ Sexual & Reproductive Health (BMJ SRH) journal will ensure old versions of guidelines will clearly signpost the newer version. iii Copyright ©Faculty of Sexual & Reproductive Healthcare 2019 FSRH guideline: Overweight, Obesity and Contraception Abbreviations used BMD bone mineral density BMI body mass index CEU Clinical Effectiveness Unit CHC combined hormonal contraception/contraceptive CI confidence interval COC combined

2019 Faculty of Sexual & Reproductive Healthcare

3. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. (PubMed)

Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. Obesity hypoventilation syndrome is commonly treated with continuous positive airway pressure or non-invasive ventilation during sleep. Non-invasive ventilation is more complex and costly than continuous positive airway pressure but might be advantageous because (...) it provides ventilatory support. To date there have been no long-term trials comparing these treatment modalities. We therefore aimed to determine the long-term comparative effectiveness of both treatment modalities.We did a multicentre, open-label, randomised controlled trial at 16 clinical sites in Spain. We included patients aged 15-80 years with untreated obesity hypoventilation syndrome and an apnoea-hypopnoea index of 30 or more events per h. We randomly assigned patients, using simple randomisation

2019 Lancet

4. WITHDRAWN: Interventions for treating obesity in children. (PubMed)

WITHDRAWN: Interventions for treating obesity in children. Child and adolescent obesity is increasingly prevalent, and can be associated with significant short- and long-term health consequences.To assess the efficacy of lifestyle, drug and surgical interventions for treating obesity in childhood.We searched CENTRAL on The Cochrane Library Issue 2 2008, MEDLINE, EMBASE, CINAHL, PsycINFO, ISI Web of Science, DARE and NHS EED. Searches were undertaken from 1985 to May 2008. References were (...) checked. No language restrictions were applied.We selected randomised controlled trials (RCTs) of lifestyle (i.e. dietary, physical activity and/or behavioural therapy), drug and surgical interventions for treating obesity in children (mean age under 18 years) with or without the support of family members, with a minimum of six months follow up (three months for actual drug therapy). Interventions that specifically dealt with the treatment of eating disorders or type 2 diabetes, or included

Full Text available with Trip Pro

2019 Cochrane

5. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. (PubMed)

Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. One anastomosis gastric bypass (OAGB) is increasingly used in the treatment of morbid obesity. However, the efficacy and safety outcomes of this procedure remain debated. We report the results of a randomised trial (YOMEGA) comparing the outcomes of OAGB versus standard Roux-en-Y gastric bypass (RYGB).This prospective (...) , multicentre, randomised non-inferiority trial, was held in nine obesity centres in France. Patients were eligible for inclusion if their body-mass index (BMI) was 40 kg/m2 or higher, or 35 kg/m2 or higher with the presence of at least one comorbidity (type 2 diabetes, high blood pressure, obstructive sleep apnoea, dyslipidaemia, or arthritis), and were aged 18-65 years. Key exclusion criteria were a history of oesophagitis, Barrett's oesophagus, severe gastro-oesophageal reflux disease resistant to proton

2019 Lancet

6. Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial. (PubMed)

Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial. Effects of nutritional interventions on the prevention of major depressive disorder (MDD) in overweight adults are unknown.To examine the effect of 2 nutritional strategies (multinutrient supplementation, food-related behavioral activation therapy (...) in the supplementation-only group were hospitalized.Among overweight or obese adults with subsyndromal depressive symptoms, multinutrient supplementation compared with placebo and food-related behavioral activation therapy compared with no therapy did not reduce episodes of major depressive disorder during 1 year. These findings do not support the use of these interventions for prevention of major depressive disorder.ClinicalTrials.gov Identifier: NCT02529423.

2019 JAMA

7. Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression: The RAINBOW Randomized Clinical Trial. (PubMed)

Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression: The RAINBOW Randomized Clinical Trial. Coexisting obesity and depression exacerbate morbidity and disability, but effective treatments remain elusive.To test the hypothesis that an integrated collaborative care intervention would significantly improve both obesity and depression at 12 months compared with usual care.The Research (...) control group (n = 205) received medical care from their personal physicians as usual, received information on routine services for obesity and depression at their clinic, and received wireless physical activity trackers. Intervention participants also received a 12-month intervention that integrated a Diabetes Prevention Program-based behavioral weight loss treatment with problem-solving therapy for depression and, if indicated, antidepressant medications.The co-primary outcome measures were BMI

2019 JAMA

8. Obesity. (PubMed)

Obesity. The role of internists in evaluating obesity is to assess the burden of weight-related disease, mitigate secondary causes of weight gain (medications, sleep deprivation), and solicit patient motivation for weight loss. Internists should assess these factors and emphasize the importance of weight loss for the individual patient. All patients wishing to lose weight should be encouraged to monitor their diet and physical activity and should be referred to high-intensity behavioral (...) programs. Some patients with obesity may also benefit from pharmacotherapy or bariatric surgery.

2019 Annals of Internal Medicine

9. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study

Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study Metabolically benign obesity remains a scientific field of considerable debate. The aim of the present work was to evaluate whether metabolically healthy obese (MHO) status is a transient condition which propagates 10-year cardiovascular disease (CVD) onset.A prospective longitudinal study was conducted during 2001-2012, the ATTICA study studying 1514 (...) (49.8%) men and 1528 (50.2%) women (aged >18 years old) free of CVD and residing in the greater Athens area, Greece. Follow-up assessment of first combined CVD event (2011-2012) was achieved in n = 2020 participants; of them, 317 (15.7%) incident cases were identified. Obesity was defined as body mass index ≥30 kg/m2 and healthy metabolic status as absence of all NCEP ATP III (2005) metabolic syndrome components (excluding waist circumference).The MHO prevalence was 4.8% (n = 146) with 28.2

2019 EvidenceUpdates

10. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial Obesity is thought to increase renal hyperfiltration, thereby increasing albuminuria and the progression of renal disease. The effect of pharmacologically mediated weight loss on renal outcomes is not well-described. Lorcaserin, a selective serotonin 2C receptor agonist that promotes appetite suppression, led to sustained weight loss without any increased risk for major adverse cardiovascular (CV (...) ) events in the CAMELLIA-TIMI 61 trial (Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61).CAMELLIA-TIMI 61 randomly assigned 12 000 overweight or obese patients with or at high risk for atherosclerotic CV disease to lorcaserin or placebo on a background of lifestyle modification. The primary renal outcome was a composite of new or worsening persistent micro- or macroalbuminuria, new or worsening chronic kidney disease, doubling

2019 EvidenceUpdates

11. Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-blind Randomized Controlled Trial

Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-blind Randomized Controlled Trial Given the role of gut microbiota in regulating metabolism, probiotics administered during pregnancy might prevent gestational diabetes mellitus (GDM). This question has not previously been studied in high-risk overweight and obese pregnant women. We aimed to determine whether probiotics (Lactobacillus rhamnosus and Bifidobacterium (...) animalis subspecies lactis) administered from the second trimester in overweight and obese women prevent GDM as assessed by an oral glucose tolerance test (OGTT) at 28 weeks' gestation. Secondary outcomes included maternal and neonatal complications, maternal blood pressure and BMI, and infant body composition.This was a double-blind randomized controlled trial of probiotic versus placebo in overweight and obese pregnant women in Brisbane, Australia.The study was completed in 411 women. GDM occurred

2019 EvidenceUpdates

12. Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study Obesity and type 2 diabetes mellitus (T2DM) are risk factors for nonalcoholic fatty liver disease, including nonalcoholic steatohepatitis. This study assessed pegbelfermin (BMS-986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM predisposed to fatty liver.In this randomized, double-blind, placebo-controlled (...)  = 0.015) and triglycerides (P = 0.037). All pegbelfermin regimens significantly increased adiponectin levels; 20-mg daily and weekly regimens decreased serum PRO-C3. Most adverse events were mild; the most frequent adverse events were injection-site bruising and diarrhea.Twelve-week pegbelfermin treatment did not impact HbA1c concentrations, but QW and higher daily doses were associated with improved metabolic parameters and fibrosis biomarkers in patients with obesity and T2DM predisposed to fatty

2019 EvidenceUpdates

13. Cost-effectiveness of incisional negative pressure wound therapy compared with standard care after caesarean section in obese women: a trial-based economic evaluation

Cost-effectiveness of incisional negative pressure wound therapy compared with standard care after caesarean section in obese women: a trial-based economic evaluation To evaluate the cost-effectiveness of incisional negative pressure wound therapy (iNPWT) in preventing surgical site infection in obese women after caesarean section.A cost-effectiveness analysis conducted alongside a clinical trial.Five obstetric departments in Denmark.Women with a pregestational body mass index (BMI) ≥30 kg/m2 (...) .We used data from a randomised controlled trial of 876 obese women who underwent elective or emergency caesarean section and were subsequently treated with iNPWT (n = 432) or a standard dressing (n = 444). Costs were estimated using data from four Danish National Databases and analysed from a healthcare perspective with a time horizon of 3 months after birth.Cost-effectiveness based on incremental cost per surgical site infection avoided and per quality-adjusted life-year (QALY) gained.The total

2019 EvidenceUpdates

14. Being overweight or obese is linked with heart disease even without other metabolic risk factors

Being overweight or obese is linked with heart disease even without other metabolic risk factors Being overweight or obese is linked with heart disease even without other metabolic risk factors Discover Portal Discover Portal Being overweight or obese is linked with heart disease even without other metabolic risk factors Published on 7 November 2017 doi: People with certain metabolic risk factors who are obese are two and a half times as likely to develop heart disease as healthy people (...) of normal weight. But those who are obese without these other risk factors still have a 28% increased risk of heart disease compared with healthy people of normal weight. This suggests excess weight should be seen as an independent risk factor, challenging the idea that people can be “fat but fit”. Metabolic risk factors for heart disease cluster together and in this large study the researchers defined “metabolically healthy” as not having; high blood pressure, raised blood sugar, high triglyceride

2019 NIHR Dissemination Centre

15. Takeaways linked to increased cardiovascular risk factors and obesity in children

Takeaways linked to increased cardiovascular risk factors and obesity in children Takeaways linked to increased cardiovascular risk factors and obesity in children Discover Portal Discover Portal Takeaways linked to increased cardiovascular risk factors and obesity in children Published on 13 February 2018 doi: Children who eat takeaways once or more each week have more body fat and higher low-density lipoprotein (LDL) “bad” cholesterol levels than those who never or hardly ever eat them (...) . Their diets were also higher in fat and lower in protein and calcium. This cross-sectional study looked in depth at eating habits and risk markers for coronary heart disease, obesity and diabetes in 2,529 children in England. Though this type of study can only show an association between takeaways and risk markers, it is one of the first of its type, and the results do give cause for concern. Increasing numbers of people are eating takeaways in the UK. Local authorities and healthcare professionals

2019 NIHR Dissemination Centre

16. Resistance training may prevent obese older people becoming frail when losing weight

Resistance training may prevent obese older people becoming frail when losing weight Resistance training may prevent obese older people becoming frail when losing weight Discover Portal Discover Portal Resistance training may prevent obese older people becoming frail when losing weight Published on 29 August 2017 doi: Combining resistance training with aerobic exercise increased physical function in older, obese adults who were following a weight loss programme. Functional improvements (...) , such as the speed to stand from a chair or to climb stairs, were greater with combination training (21%) than with either type of exercise performed alone (14%). This randomised controlled trial assigned 160 obese adults in the USA (aged over 65, mostly educated white females) to the different types of exercise for six months. Those exercising lost about 9% body weight on their diets. Resistance training was most effective for preventing loss of muscle and bone mass. This highlights the importance of strength

2019 NIHR Dissemination Centre

17. Intensive lifestyle interventions can help obese young people lose weight

Intensive lifestyle interventions can help obese young people lose weight Intensive lifestyle interventions can help obese young people lose weight Discover Portal Discover Portal Intensive lifestyle interventions can help obese young people lose weight Published on 19 September 2017 doi: Obese children and adolescents can lose up to seven pounds over six to 12 months when they engage in at least 52 hours of behaviour-based lifestyle interventions. Minimal benefit was seen with shorter contact (...) time, with less than 25 hours ineffective. The control group gained weight. Rising obesity in the young is a global concern, which may lead to high rates of obesity-related diseases in adulthood. This review identified trials covering various weight management strategies. Lifestyle-based-interventions with sufficient contact time – as recommended by UK guidelines – showed clear benefits with no evidence of harms. Investing in effective strategies to manage child obesity will ultimately save

2019 NIHR Dissemination Centre

18. A school-based obesity prevention programme was ineffective

A school-based obesity prevention programme was ineffective A school-based obesity prevention programme was ineffective Discover Portal Discover Portal A school-based obesity prevention programme was ineffective Published on 10 April 2018 doi: A school-based healthy lifestyle programme delivered to 6-7-year-old children and their parents made no difference to children’s weight, diet or activity levels. Around 1 in 4 remained overweight or obese. The NIHR-funded year-long programme was delivered (...) in 54 primary schools in one region of England. Teachers were trained to provide an additional 30 minutes of physical activity a day and deliver cookery workshops with parents each term. It also included activities with a local football club, Aston Villa. Children in schools that took part were no less likely to be overweight or obese after 15 or 30 months, and their diet and exercise levels did not improve. Less than one in six schools managed to deliver the activity sessions as planned

2019 NIHR Dissemination Centre

19. Weight loss surgery is value for money in selected people with severe obesity

Weight loss surgery is value for money in selected people with severe obesity Weight loss surgery is value for money in selected people with severe obesity Discover Portal Discover Portal Weight loss surgery is value for money in selected people with severe obesity Published on 23 August 2016 doi: Surgery is a cost-effective method of weight loss for severely and morbidly obese people. This study of general practice data compared health costs and outcomes for people with severe or morbid (...) obesity who underwent surgery and those who did not. Surgery was associated with a reduced chance of developing diabetes and an increased chance of remission in people with diabetes. It was more cost-effective – using NHS thresholds – for morbidly obese people who had diabetes, than for those without diabetes. Weight loss surgery either reduces the amount of food people can consume or the amount of energy they can absorb from food. A quarter of UK adults are obese, with 3.6% of women and 1.8% of men

2019 NIHR Dissemination Centre

20. A total diet replacement programme helped obese people lose weight and keep weight off

A total diet replacement programme helped obese people lose weight and keep weight off Total diet replacement for weight loss in obesity Discover Portal Discover Portal A total diet replacement programme helped obese people lose weight and keep weight off Published on 18 December 2018 doi: A programme of weekly behavioural support with total diet replacement led to over 7kg greater weight loss than usual care in primary care. This weight loss was maintained for a year after starting the 8-12 (...) . After eight weeks of this low calorie diet, conventional meals were gradually reintroduced. This trial provides evidence that the rapid weight loss from these replacement diets can be maintained for a reasonable time and so could be considered as a treatment option for anyone who is obese and needs support to lose weight. Share your views on the research. Why was this study needed? In 2016, 26% of adults in England were obese. Obesity can lead to several medical conditions, including heart disease

2019 NIHR Dissemination Centre